- 1 Community occurrence of metapneumovirus, influenza A, and respiratory syncytial virus (RSV)
- 2 inferred from wastewater solids during the winter 2022-2023 tripledemic
- 3
- 4 Authors
- 5 Alexandria B. Boehm^{1*}, Marlene K. Wolfe², Bradley White³, Bridgette Hughes³, Dorothea Duong³,
- 6 Amanda Bidwell¹
- 7
- 8

9 Affiliations

- Department of Civil & Environmental Engineering, School of Engineering and Doerr School of
 Sustainability, Stanford University, Stanford, CA, USA
- 12 2. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
- 13 University, Atlanta, GA, USA
- 14 3. Verily Life Sciences, South San Francisco, CA, USA
- 15
- 16
- 17
- 18 *corresponding author: Alexandria Boehm (aboehm@stanford.edu)
- 19
- 20
- 21

23 Abstract

| 25 | Wastewater monitoring can provide insights into respiratory disease occurrence in communities |
|----|--|
| 26 | that contribute to the wastewater system. Using daily measurements of RNA of influenza A |
| 27 | (IAV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV), as well as |
| 28 | SARS-CoV-2 in wastewater solids from eight publicly owned treatment works in the Greater San |
| 29 | Francisco Bay Area of California between July 2022 until early May 2023, we identify a |
| 30 | "tripledemic" when concentrations of IAV, RSV, and SARS-CoV-2 peaked at approximately the |
| 31 | same time. HMPV was also widely circulating. We designed novel hydrolysis probe RT-PCR |
| 32 | assays for different IAV subtype makers to discern that the dominant circulating IAV subtype |
| 33 | was H3N2. We show that wastewater data can be used to identify onset and offset of |
| 34 | wastewater disease occurrence events that can provide insight into disease epidemiology and |
| 35 | timely, localized information to inform hospital staffing and clinical decision making to respond to |
| 36 | circulating viruses. Whereas RSV and IAV wastewater events were mostly regionally coherent, |
| 37 | HMPV events displayed localized occurrence patterns. |
| 20 | |

40 Introduction

41

Acute respiratory illness (ARI) accounts for a large burden of infectious disease^{1,2}; and is a 42 43 leading cause of death for children under 5 globally³. ARI surveillance in the United States 44 (US), and much of the world, is passive, relying on institutions to identify specific diseases 45 through clinical specimens and regularly reporting results to a government agency. As a result, 46 ARI surveillance is biased towards identifying infections in individuals with co-morbidities and/or where symptoms are severe⁴. Resultant lack of knowledge on occurrence and trends in 47 48 circulating respiratory disease dynamics limits institutional awareness to guide public health 49 response and clinical decision making. Additionally, the lack of robust, unbiased data on 50 disease occurrence limits efforts to understand disease epidemiology. 51 52 During the COVID-19 pandemic, the circulation of respiratory viruses changed dramatically according to both clinical surveillance^{5,6} and wastewater monitoring⁷. For example, in the US, 53 54 there was limited influenza or RSV circulation in the northern hemisphere winter of 2021-55 2022^{5,8}. During winter 2022-2023, the US experienced a "tripledemic" of respriatory viruses as 56 clinics and hospitals recorded large numbers SARS-CoV-2, influenza, and RSV infections, at times overwhelming hospital capacity particularly in pediatric units⁹. Nearly 40% of United 57 58 States households reported being infected by SARS-CoV-2, influenza, or RSV during the 59 tripledemic period¹⁰.

60

In the present study, we explore the potential for wastewater monitoring, also referred to as wastewater-base epidemiology, to inform the onset and progression of important respiratory viruses during this tripledemic period in the United States. We measured concentrations of genomic nucleic-acids of influenza A (IAV), RSV, SARS-CoV-2, as well as human metapneumovirus (HMPV) in wastewater solids daily in eight publicly owned treatment works

66 (POTWs) in the Greater San Francisco Bay Area of California. USA during winter 2022-2023. 67 We find that the unusual co-occurrence of the onset of these outbreaks is identifiable using 68 wastewater monitoring, and moreover HMPV was also circulating. Whereas clinical testing data 69 are affected by an individual's test seeking behavior and test availability^{11–13}, as well as institutional reporting delays which can be weeks in duration^{14,15}, wastewater data are available 70 71 within 24 hours of sample collection and provide information about the entire community 72 contributing to the wastewater system. We posit that wastewater can be used to help identify 73 the onset and offset of respiratory virus transmission events, as well as the peak of such events. 74 This in turn can inform clinical decision making as well as institutional public health messaging 75 and individual behaviors. 76 77 Methods 78 79 Sample collection. Eight POTWs located in the greater San Francisco Bay Area (extending to 80 Sacramento) in California, USA contributed daily samples of wastewater settled solids for the 81 prospective study (Figure S1, additional POTW details are in Wolfe et al.¹⁶). Approximately 82 50 ml of settled solids were collected daily between 7/1/22 (month/day/year format) and 5/7/23. 83 Additional details of sample collection are in the SI. Samples were immediately stored at 4°C 84 and transported to the laboratory where processing began within 6 h of collection. 2472 samples 85 were collected. 86 Sample preparation and RNA extraction. Details of sample preparation and nucleic-acid 87 extraction have been described in detail elsewhere^{7,16–18} and are described briefly in the SI. 88 89 RNA was extracted from 10 replicate aliguots per sample and then subjected to an inhibitor 90 removal step. Extraction-negative controls (water) and extraction-positive controls were 91 extracted using the same protocol as the homogenized samples. The positive controls consisted

92 of SARS-CoV-2 genomic RNA (ATCC VR-1986D), Twist Synthetic Influenza A H3N2 RNA 93 Control (Twist 103002), Intact RSV B virus (Zepto NATFVP-NNS), and a gene block (double-94 stranded DNA [dsDNA] purchased from IDT) for the HMPV target in the BCoV-spiked DNA/RNA 95 shield solution described above. 96 97 Droplet digital PCR. RNA extracts were used as template in digital droplet RT-PCR assays for 98 PMMoV, BCoV, SARS-CoV-2 N, IAV M, RSV N, and HMPV L gene targets in multiplex assays which have been previously published^{7,19}. Each of the 10 replicate nucleic-acid extracts were 99 100 run in their own well. Assays were multiplexed using the probe mixing approach (see SI and Table S1). PMMoV is highly abundant in wastewater globally²⁰ and is used here as an internal 101 102 recovery and fecal strength control²¹. Undiluted extract was used for the human viral assay 103 template, and a 1:100 dilution of the extract was used for the BCoV/PMMoV assay template. 104 Details of the digital RT-PCR have been published and are included in the SI. 105 106 Concentrations of RNA targets were converted to concentrations per dry weight of solids in units 107 of cp/g using dimensional analysis. The total error is reported as standard deviations and 108 includes the errors associated with the Poisson distribution and the variability among the 10 109 replicates. BCoV recovery was determined by normalizing the BCoV concentration by the 110 expected concentration given the value measured in the spiked DNA/RNA shield. BCoV 111 recovery was used as a process control and not used in the calculation of concentrations; 112 samples were rerun in cases where the recovery of BCoV was less than 1%. 113 114 Influenza subtypes. We designed and tested novel RT-PCR primers and internal hydrolysis 115 probes targeting the H1 subtype of the hemagluttanin (HA) gene, H3 subtype of the HA gene, 116 N1 subtype of the neuraminidase (NA) gene, and N2 subtype of the NA gene of IAV. Primers

and probes were then screened for specificity in silico, and in vitro against other respiratory andenteric viruses (see SI, Table S2).

119

We retrospectively tested two samples per week between 7/1/22 and 3/31/23 (covering most of
the IAV wastewater event) from SJ POTW for the four influenza A subtype markers (N1, N2, H1,
H3). We also re-analyzed the samples to quantify the IAV M gene in order to report the ratio of
the subtype markers to M gene (see SI).

124

125 **Clinical data.** We used state-aggregated weekly clinical sample positivity rates from sentinel

126 laboratories for IAV, RSV and HMPV. IAV, RSV, and a fraction of the HMPV data are publicly

127 available²², the remaining HMPV data were provided by California Department of Public Health

128 (CDPH). State-aggregated daily positivity rates for COVID-19 are publicly available

129 (https://data.chhs.ca.gov/dataset/covid-19-time-series-metrics-by-county-and-state).

130

Data analysis. Human viral RNA concentrations were normalized by PMMoV RNA; 5-d trimmed averages were used to visualize data and identify the date of their peak maximum concentrations. The onset dates of IAV, RSV, and HMPV wastewater events were identified as the first day for which all samples in a 14-d look back period had concentration higher than 2000 copies/g,, which is approximately twice the lowest detectable concentration. The offset dates of IAV, RSV, and HMPV wastewater events were identified as the first day after an onset event for which only 7 samples during a 14-d look back period had concentrations over 2000 copies/g.

138

139 We tested whether PMMoV-normalized viral RNA concentrations at each POTW were

140 correlated to the same measurements at the other eight POTWs (28*4 = 112 hypothesis tests),

141 and whether PMMoV-normalized viral RNA concentrations were correlated within POTWs (48

tests) using Kendall's tau as these data tend to not be normally distributed. We also tested the

| 143 | hypothesis that PMMoV-normalized viral RNA correlated to state-aggregated positivity rates (32 |
|-----|---|
| 144 | tests). Since IAV, RSV, and HMPV positivity rates are aggregated weekly, we used weekly |
| 145 | median PMMoV-normalized viral RNA concentrations to test the hypothesis. We used a p value |
| 146 | of 0.00026 (0.05/192) which corresponds to alpha= 0.05 with a Bonferroni correction. Results |
| 147 | were similar when analyses were carried out with variables that were not PMMoV-normalized. |
| 148 | |
| 149 | This study was reviewed by the State of California Health and Human Services Agency |
| 150 | Committee for the Protection of Human Subjects and determined to be Exempt from oversight. |
| 151 | Wastewater data are publicly available (https://purl.stanford.edu/gp563rt4747). Data collected |
| 152 | between 7/1/22 and 12/31/22 are publicly available through a Data Descriptor ²³ . |
| 153 | |
| 154 | Results |
| 155 | |
| 156 | QA/QC. Results are reported as suggested in the Environmental Microbiology Minimal |
| 157 | Information guidelines ²⁴ (Figure S2). Extraction and PCR negative and positive controls |
| 158 | performed as expected (negative and positive, respectively). Median BCoV recovery in these |
| 159 | solids samples was 1.2 (interquartile range = 0.92-1.72, n=2472); values greater than 1 are |
| 160 | likely a result of uncertainty in quantifying the amount of BCoV spiked in the DNA/RNA shield. |
| 161 | |
| 162 | Novel IAV subtype assay sensitivity and specificity. In silico analysis indicated no cross |
| 163 | reactivity of the novel RT-PCR probe-based assays (Table S3) with sequences deposited in |
| 164 | NCBI. The novel assays for IAV N1, N2, H1 and H3 were tested in vitro against non-target viral |
| 165 | gRNA as well as target gRNA. No cross reactivity was observed. |
| 166 | |
| 167 | Viral RNA in wastewater solids. Viral concentrations were dynamic over the project duration, |
| 168 | with most showing elevated concentrations in the winter (Figure 1). PMMoV-normalized HMPV, |

169 IAV, RSV, and SARS-CoV-2 RNA concentrations were each positively and significantly

associated between the eight POTWs, respectively (IAV tau: 0.49 to 0.64, RSV tau: 0.53 to

171 0.71, HMPV tau: 0.37 to 0.56, SARS-CoV-2 tau: 0.27 to 0.45, all p<10⁻¹², Figure S3) suggesting

- 172 coarse temporal coherence across the region.
- 173
- 174 Within each POTW, PMMoV-normalized IAV, RSV, HMPV, and SARS-CoV-2 RNA
- 175 concentrations were generally positively associated with each other suggesting coherence
- 176 within a POTW (tau: 0.15 to 0.56, all p < 0.00026, depending on POTW and specific
- 177 measurements, Figure S4). The exceptions are at PA where HMPV was not associated with
- 178 IAV, at Gil where HMPV was not associated with SARS-CoV-2, and at SAC and Ocean, where

179 HMPV was not significantly associated with IAV or SARS-CoV-2. Taus were generally highest

180 between IAV and RSV, and slowest between HMPV and both IAV and SARS-CoV-2.

181

- State-aggregregated clinical specimen positivity rates for IAV, RSV, HMPV, and SARS-CoV-2
 show peaks in winter months (Figure S5). Weekly median PMMoV-normalized concentrations of
 all viruses were significantly, positively correlated with the associated clinical positivity rate (see
 SI, all p<10⁻⁶).
- 186

The peak wastewater concentrations varied across POTWs for the different viral targets (Table
1). Peak RSV occurred between 11/25/22 and 12/14/22, peak IAV occurred between 26 Nov
and 13 Dec, and peak HMPV occurred between 11/26/22 and 3/30/23, depending on POTW.
For context, peak SARS-CoV-2 occurred between 11/30/22 and 3/16/23.

191

192 We identified dates of wastewater event onsets and offsets for RSV, IAV, and HMPV, but not for

193 SARS-CoV-2 as its levels were such that the entire period of the study would be defined as a

194 wastewater event (Table 1). We observed wintertime RSV wastewater events at all 8 POTWs

| 195 | with onsets between 9/17/22 and 10/24/22, and offsets between 3/20/23 and 4/29/23, |
|-----|---|
| 196 | depending on POTW. The period of time between onset and offset varied between 147 and 215 |
| 197 | days (median = 190 days). |
| 198 | |
| 199 | We observed a summer IAV wastewater event at two POTWs (SJ and PA); both onset on |
| 200 | 7/14/22 and offset on 7/23/22 (SJ) and 9/21/22 (PA). We observed wintertime wastewater |
| 201 | events at all 8 POTWs with onsets between 10/26/22 and 11/18/22 and offsets between 1/25/23 |
| 202 | and 3/3/23. The duration of the wintertime events ranged from 73 and 122 days (median = 104 |
| 203 | days). IAV subtype analysis at SJ did not detect N1, but detected N2, H1, and H3. When |
| 204 | detected, the ratio of N2/IAV ranged from 0.3 to over 1 (median = 0.6), H1/IAV ranged from from |
| 205 | 0.03 to 0.35 (median = 0.07), and H3/IAV ranged from from 0.1 to 0.4 (median = 0.2) (Figure |
| 206 | S6). |
| 207 | |
| 208 | We observed a fall HMPV wastwater event at one POTW (SE) with onset on 9/1/22 and offset |
| 209 | on 9/24/22. We observed wintertime HMPV wastewater events for all 8 POTWs with onsets |
| 210 | between 8/6/22 and 12/3/22. Data from the 8 POTWs indicated on 5/7/23, the end of the study, |
| 211 | that none of the HMPV events had offset suggesting minimal durations (assuming offset |
| 212 | occurred on 5/8, the day after the study ended) between 156 and 275 days (median = 187 |
| 213 | days). |
| 214 | |
| 215 | Discussion |
| 216 | |
| 217 | Influenza A, RSV, and SARS-CoV-2 RNA in wastewater solids in the Greater San Francisco |
| 218 | Bay Area of California are reflective of the winter 2022-2023 "tripledemic" when cases of |
| 219 | influenza, RSV, and COVID-19 increased dramatically with similar onset periods, sometimes |
| 220 | overwhelming hospital capacity ⁹ . Wastewater monitoring of human metapneumovirus (HMPV) |

221 RNA suggests HMPV was also circulating in communities during the tripledemic, but with 222 slightly different outbreak timing and continued activity after IAV and RSV offset in most areas. HMPV was discovered in 2001²⁵ and clinical presentation can be indistinguishable from 223 influenza and RSV²⁶. Hospitalization rates associated with HMPV for children are similar to 224 those for influenza²⁷. Although there are vaccines available for IAV²⁸ and the first vaccine was 225 226 approved by the FDA for RSV in 2023 (although only for adults age > 60 yo)^{29,30}, there is no HMPV vaccine currently available³¹. IAV subtype analysis suggested that H3N2 was more 227 common than H1N1, consistent with subtyping of clinical samples²². 228 229 230 Wastewater data was able to resolve information on occurrence patterns at higher resolution 231 than clinical data, showing differences in occurrence patterns of IAV, RSV, SARS-CoV-2, and 232 HMPV community infections. For IAV, we identified two localized summertime events at two

identified at one POTW located in San Francisco County, neither of which were reflected in their
 respective state-aggregated positivity rate data.

POTWs located 15 km apart in Santa Clara County and a late localized fall HMPV event was

236

233

Wintertime wastewater events were evident for IAV, RSV, and HMPV, but their characteristics
differed. IAV events were temporally coherent throughout the region with onsets, peaks, and

239 offsets occurring at all POTWs within the same three, three, and five week windows,

240 respectively. RSV events were also regionally temporally coherent; all POTWs had onsets,

241 peaks, and offsets within the same five, three, and five week windows, respectively. However,

242 wintertime RSV onset and offsets occurred one month earlier and later, respectively, than those

243 of IAV across all POTWs, a pattern also discernible in the state-aggregated clinical data. RSV

244 peak concentrations occurred at the same time as peak IAV concentrations. SARS-CoV-2

concentrations also had local peaks at the same time as RSV and IAV suggesting community

infections reach their height in unison, consistent with reports of the tripledemic overwhelming
 some hospital capacities⁹.

248

249 HMPV wastewater events differed widely in the timing of onset and peak among the eight 250 POTWs, suggesting localized dynamics; onsets dates varied by up to 4 months and the timing 251 of the peak varied by up to 5 months. Localized HMPV dynamics is further supported by the 252 relatively weak correlations between HMPV concentrations and concentrations of the other 253 viruses that showed patterns of regional coherence. Although HMPV concentrations were 254 positively associated with the state-aggregated positivity rate data, there are clearly localized 255 dynamics in the wastewater events that are not reflected in the state-aggregated clinical data. 256 More localized data on HMPV circulation is not available as testing is extremely limited⁷. 257 Previous studies of clinical HMPV infections suggest variable seasonal infection from year-toyear in contrast to typical patterns in seasonal RSV and IAV infections²⁷. 258 259

A global systematic review³² indicates that seasonal IAV, RSV, and HMPV epidemics typically 260 261 overlap. RSV epidemics typically start earlier than IAV epidemics by 0.3 months in temperate 262 regions³². In our study RSV wastewater events onset 1.2 months (median) before IAV. The 263 same review indicates IAV and RSV epidemics in temperate areas are 3.8 and 4.6 months in 264 duration, respectively. Wastewater events for IAV and RSV were 3.5 and 4.8 months in duration 265 (medians). Temperate HMPV epidemics began 1.7 months after RSV and were 4.8 months in 266 duration. In the present study, HMPV wastewater events began 1 month after RSV (median), 267 and were at least 6.3 months in duration.

268

While the clinical test positivity data used here provides insight into disease circulation during the study time period, there is no data on community incidence or prevalence of IAV, RSV, or HMPV in the study area. Additionally, data on COVID-19 incidence and prevalence degraded

during this time period owing to the wide availability of at home rapid tests^{12,33}, the results of 272 273 which are not reportable to public health agencies in our study area. IAV, RSV, HMPV, and 274 COVID-19 test positivity rates serve as proxies for trends in disease occurrence, but it is 275 important to acknowledge that the rates reflect those of severely symptomatic cases. There is 276 also a significant delay in those data being available, usually with results available and updated 277 2-4 weeks after specimen collection. Wastewater represents composite biological samples from 278 an entire community including those who are asymptomatic or mildly symptomatic. Wastewater 279 therefore compliments data on clinical test positivity. Given the delays associated with the 280 positivity rate data, and the sparseness of localized positivity rate data, wastewater can serve as 281 an indicator of the first onsets of localized, community infections. While spatial and temporal 282 coherence was observed for IAV and RSV events, HMPV showed more localized dynamics. 283 This has been shown previously for other diseases; localized dynamics of mpox were also evident from wastewater monitoring³⁴. We explored other methods of identifying wastewater 284 285 events including using different concentration thresholds and look-back periods. All gave similar 286 relative results among the viruses; a public health organization could decide on data analysis 287 methods for identifying wastewater events that were fit for their purposes.

288

Supporting Information. Additional methodological details as well as Tables S1-S3, and
Figures S1-S6.

291

Acknowledgements. We acknowledge the numerous people who contributed to wastewater sample collection and Allegra Koch for her support with the literature review. This research was performed on the ancestral and unceded lands of the Muwekma Ohlone people. We pay our respects to them and their Elders, past and present, and are grateful for the opportunity to live and work here.

297

| 298 299 | | |
|--|------------|--|
| 300 301 | Refe | erences |
| 302 303 | (1) | Jin, X.; Ren, J.; Li, R.; Gao, Y.; Zhang, H.; Li, J.; Zhang, J.; Wang, X.; Wang, G. Global Burden of Upper Respiratory Infections in 204 Countries and Territories, from 1990 to |
| 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 320 321 322 324 325 326 327 328 329 331 331 332 324 325 326 327 328 329 331 332 331 332 331 332 331 332 331 332 331 332 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 331 332 333 334 333 334 335 334 335 355 355 355 355 355 355 | (1) (2) | Jin, X.; Ren, J.; Li, R.; Gao, Y.; Zhang, H.; Li, J.; Zhang, J.; Wang, X.; Wang, G. Global Burden of Upper Respiratory Infections in 204 Countries and Territories, from 1990 to 2019. <i>eClinicalMedicine</i> 2021, 37. https://doi.org/10.1016/j.eclinm.2021.100986. Vos, T.; Lin, S. S.; Abbafati, C.; Abbas, K. M.; Abbasi, M.; Abbasifard, M.; Abbasi-Kangevari, M.; Abbastabar, H.; Abd-Allah, F.; Abdelalim, A.; Abdollahi, M.; Abdollahpour, I.; Abolnassani, H.; Aboyans, V.; Abrams, E. M.; Abreu, L. G.; Abrigo, M. R. M.; Abu-Raddad, L. J.; Abushouk, A. I.; Acebedo, A.; Ackerman, I. N.; Adabi, M.; Adamu, A. A.; Adebayo, O. M.; Adekanmbi, V.; Adelson, J. D.; Adetokunboh, O. O.; Adham, D.; Afshari, M.; Afshin, A.; Agardh, E. E.; Agarwal, G.; Agesa, K. M.; Aghaali, M.; Aphamir, S. M. K.; Agrawal, A.; Ahmadi, T.; Ahmadi, A.; Ahmadi, M.; Ahmadieh, H.; Ahmadpour, E.; Akalu, T. Y.; Akinyemi, R. O.; Akinyemiju, T.; Akombi, B.; Al-Aly, Z.; Alarn, K.; Alam, N.; Alam, S.; Alam, T.; Alanzi, T. M.; Albertson, S. B.; Alcalde-Rabanal, J. E.; Alema, N. M.; Ali, S.; Alicantor, G.; Alijanzadeh, M.; Alhina, C.; Alipour, V.; Aljunid, S. M.; Alla, F.; Allebeck, P.; Almasi-Hashiani, A.; Alonso, J.; Al-Raddadi, R. M.; Altirkawi, K. A.; Alvis-Guzman, N.; Alvis-Zakzuk, N. J.; Amini, S.; Amini-Rarani, M.; Anrinorroaya, A.; Amiri, F.; Amit, A. M. L.; Amugi, D. A.; Amul, G. G. H.; Anderlini, D.; Andrei, C. L.; Andrei, T.; Anjomshoa, M.; Ansari, F.; Ansari, I.; Ansari-Moghaddam, A.; Antonio, C. A. T.; Antony, C. M.; Antriyandarti, E.; Anvari, D.; Anwer, R.; Arabloo, J.; Arab-Zozani, M.; Aravkin, A. Y.; Ariani, F.; Arilov, J.; Aryal, K. K.; Arzani, A.; Asadi-Aliabadi, M.; Asadi-Pooya, A. A.; Asghari, B.; Ayanore, M. A.; Aynalem, Y. A.; Azari, S.; Azarian, G.; Azene, Z. N.; Babaee, E.; Badawi, A.; Bagherzadeh, M.; Bahshaei, M. H.; Bakhtiari, A.; Balakrishnan, S.; Balalla, S.; Balassyano, S.; Banach, M.; Banik, P. C.; Bannick, M. S.; Bante, A. B.; Baraki, A. G.; Barooza, M. A.; Bagherzadeh, M.; Banik, P. C.; Bannick, M. S.; Bante, A. B.; |
| 334 335 | | Butt, Z. A.; Caetano dos Santos, F. L.; Cámera, L. L. A.; Campos-Nonato, I. R.; Car, J.; Cárdenas, R.; Carreras, G.; Carrero, J. J.; Carvalho, F.; Castaldelli-Maia, J. M.; |
| 336 337 | | Castañeda-Orjuela, C. A.; Castelpietra, G.; Castle, C. D.; Castro, F.; Catalá-López, F.; Causey, K.; Cederroth, C. R.; Cercy, K. M.; Cerin, E.; Chandan, J. S.; Chang, A. R.; |
| 338 339 | | Charlson, F. J.; Chattu, V. K.; Chaturvedi, S.; Chimed-Ochir, O.; Chin, K. L.; Cho, D. Y.; Christensen, H.; Chu, DT.; Chung, M. T.; Cicuttini, F. M.; Ciobanu, L. G.; Cirillo, M.; |
| 340 341 | | Collins, E. L.; Compton, K.; Conti, S.; Cortesi, P. A.; Costa, V. M.; Cousin, E.; Cowden, R. G.; Cowie, B. C.; Cromwell, F. A.; Cross, D. H.; Crowe, C. S.; Cruz, J. A.; Cunningham, M.; |
| 342 | | Dahlawi, S. M. A.; Damiani, G.; Dandona, L.; Dandona, R.; Darwesh, A. M.; Daryani, A.; |
| 343 | | Das, J. K.; Das Gupta, R.; das Neves, J.; Dávila-Cervantes, C. A.; Davletov, K.; De Leo, |
| ১44 345 | | D., Deall, F. E., Deoleene, N. N., Deen, A., Degennarul, L., Dellavalle, K. P., Demeke, F. M. Demsie, D. G. Denova-Gutiérrez, F.: Dereje, N. D.: Dervenie, N.: Dessi, P.: Desslow |
| 346 | | A · Dessie G A · Dharmaratne S D · Dhungana G P · Dianatinasah M · Diaz D · Dibaii |
| 347 | | Forooshani, Z. S.; Dingels, Z. V.; Dirac, M. A.; Djalalinia, S.; Do, H. T.; Dokova, K.; |

348 Dorostkar, F.: Doshi, C. P.: Doshmangir, L.: Douiri, A.: Doxev, M. C.: Driscoll, T. R.: 349 Dunachie, S. J.; Duncan, B. B.; Duraes, A. R.; Eagan, A. W.; Ebrahimi Kalan, M.; 350 Edvardsson, D.; Ehrlich, J. R.; El Nahas, N.; El Sayed, I.; El Tantawi, M.; Elbarazi, I.; 351 Elgendy, I. Y.; Elhabashy, H. R.; El-Jaafary, S. I.; Elyazar, I. R.; Emamian, M. H.; Emmons-352 Bell, S.; Erskine, H. E.; Eshrati, B.; Eskandarieh, S.; Esmaeilnejad, S.; Esmaeilzadeh, F.; 353 Esteghamati, A.; Estep, K.; Etemadi, A.; Etisso, A. E.; Farahmand, M.; Faraj, A.; Fareed, 354 M.; Faridnia, R.; Farinha, C. S. e S.; Farioli, A.; Faro, A.; Faruque, M.; Farzadfar, F.; 355 Fattahi, N.; Fazlzadeh, M.; Feigin, V. L.; Feldman, R.; Fereshtehnejad, S.-M.; Fernandes, 356 E.; Ferrari, A. J.; Ferreira, M. L.; Filip, I.; Fischer, F.; Fisher, J. L.; Fitzgerald, R.; Flohr, C.; 357 Flor, L. S.; Foigt, N. A.; Folayan, M. O.; Force, L. M.; Fornari, C.; Foroutan, M.; Fox, J. T.; 358 Freitas, M.; Fu, W.; Fukumoto, T.; Furtado, J. M.; Gad, M. M.; Gakidou, E.; Galles, N. C.; 359 Gallus, S.; Gamkrelidze, A.; Garcia-Basteiro, A. L.; Gardner, W. M.; Geberemariyam, B. S.; 360 Gebrehiwot, A. M.; Gebremedhin, K. B.; Gebreslassie, A. A. A. A.; Gershberg Hayoon, A.; 361 Gething, P. W.; Ghadimi, M.; Ghadiri, K.; Ghafourifard, M.; Ghajar, A.; Ghamari, F.; 362 Ghashghaee, A.; Ghiasvand, H.; Ghith, N.; Gholamian, A.; Gilani, S. A.; Gill, P. S.; 363 Gitimoghaddam, M.; Giussani, G.; Goli, S.; Gomez, R. S.; Gopalani, S. V.; Gorini, G.; 364 Gorman, T. M.; Gottlich, H. C.; Goudarzi, H.; Goulart, A. C.; Goulart, B. N. G.; Grada, A.; 365 Grivna, M.; Grosso, G.; Gubari, M. I. M.; Gugnani, H. C.; Guimaraes, A. L. S.; Guimarães, 366 R. A.; Guled, R. A.; Guo, G.; Guo, Y.; Gupta, R.; Haagsma, J. A.; Haddock, B.; Hafezi-367 Nejad, N.; Hafiz, A.; Hagins, H.; Haile, L. M.; Hall, B. J.; Halvaei, I.; Hamadeh, R. R.; 368 Hamagharib Abdullah, K.; Hamilton, E. B.; Han, C.; Han, H.; Hankey, G. J.; Haro, J. M.; 369 Harvey, J. D.; Hasaballah, A. I.; Hasanzadeh, A.; Hashemian, M.; Hassanipour, S.; 370 Hassankhani, H.; Havmoeller, R. J.; Hay, R. J.; Hay, S. I.; Hayat, K.; Heidari, B.; Heidari, 371 G.: Heidari-Soureshiani. R.: Hendrie. D.: Henrikson. H. J.: Henry. N. J.: Herteliu. C.: 372 Hevdarpour, F.; Hird, T. R.; Hoek, H. W.; Hole, M. K.; Holla, R.; Hoogar, P.; Hosgood, H. 373 D.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Hoy, D. G.; Hsairi, M.; Hsieh, 374 V. C.; Hu, G.; Huda, T. M.; Hugo, F. N.; Huynh, C. K.; Hwang, B.-F.; Iannucci, V. C.; 375 Ibitoye, S. E.; Ikuta, K. S.; Ilesanmi, O. S.; Ilic, I. M.; Ilic, M. D.; Inbaraj, L. R.; Ippolito, H.; 376 Irvani, S. S. N.; Islam, M. M.; Islam, M.; Islam, S. M. S.; Islami, F.; Iso, H.; Ivers, R. Q.; Iwu, 377 C. C. D.; Iyamu, I. O.; Jaafari, J.; Jacobsen, K. H.; Jadidi-Niaragh, F.; Jafari, H.; Jafarinia, 378 M.; Jahagirdar, D.; Jahani, M. A.; Jahanmehr, N.; Jakovljevic, M.; Jalali, A.; Jalilian, F.; 379 James, S. L.; Janjani, H.; Janodia, M. D.; Jayatilleke, A. U.; Jeemon, P.; Jenabi, E.; Jha, R. 380 P.; Jha, V.; Ji, J. S.; Jia, P.; John, O.; John-Akinola, Y. O.; Johnson, C. O.; Johnson, S. C.; 381 Jonas, J. B.; Joo, T.; Joshi, A.; Jozwiak, J. J.; Jürisson, M.; Kabir, A.; Kabir, Z.; Kalani, H.; Kalani, R.; Kalankesh, L. R.; Kalhor, R.; Kamiab, Z.; Kanchan, T.; Karami Matin, B.; Karch, 382 383 A.; Karim, M. A.; Karimi, S. E.; Kassa, G. M.; Kassebaum, N. J.; Katikireddi, S. V.; 384 Kawakami, N.; Kayode, G. A.; Keddie, S. H.; Keller, C.; Kereselidze, M.; Khafaie, M. A.; 385 Khalid, N.: Khan, M.: Khatab, K.: Khater, M. M.: Khatib, M. N.: Khavamzadeh, M.: 386 Khodayari, M. T.; Khundkar, R.; Kianipour, N.; Kieling, C.; Kim, D.; Kim, Y.-E.; Kim, Y. J.; 387 Kimokoti, R. W.; Kisa, A.; Kisa, S.; Kissimova-Skarbek, K.; Kivimäki, M.; Kneib, C. J.; 388 Knudsen, A. K. S.; Kocarnik, J. M.; Kolola, T.; Kopec, J. A.; Kosen, S.; Koul, P. A.; 389 Koyanagi, A.; Kravchenko, M. A.; Krishan, K.; Krohn, K. J.; Kuate Defo, B.; Kucuk Bicer, 390 B.; Kumar, G. A.; Kumar, M.; Kumar, P.; Kumar, V.; Kumaresh, G.; Kurmi, O. P.; Kusuma, 391 D.; Kyu, H. H.; La Vecchia, C.; Lacey, B.; Lal, D. K.; Lalloo, R.; Lam, J. O.; Lami, F. H.; 392 Landires, I.; Lang, J. J.; Lansingh, V. C.; Larson, S. L.; Larsson, A. O.; Lasrado, S.; Lassi, 393 Z. S.; Lau, K. M.-M.; Lavados, P. M.; Lazarus, J. V.; Ledesma, J. R.; Lee, P. H.; Lee, S. W. 394 H.; LeGrand, K. E.; Leigh, J.; Leonardi, M.; Lescinsky, H.; Leung, J.; Levi, M.; Lewington, 395 S.; Li, S.; Lim, L.-L.; Lin, C.; Lin, R.-T.; Linehan, C.; Linn, S.; Liu, H.-C.; Liu, S.; Liu, Z.; 396 Looker, K. J.; Lopez, A. D.; Lopukhov, P. D.; Lorkowski, S.; Lotufo, P. A.; Lucas, T. C. D.; 397 Lugo, A.; Lunevicius, R.; Lyons, R. A.; Ma, J.; MacLachlan, J. H.; Maddison, E. R.; Maddison, R.; Madotto, F.; Mahasha, P. W.; Mai, H. T.; Majeed, A.; Maled, V.; Maleki, S.; 398

399 Malekzadeh, R.: Malta, D. C.: Mamun, A. A.: Manafi, A.: Manafi, N.: Manguerra, H.: 400 Mansouri, B.; Mansournia, M. A.; Mantilla Herrera, A. M.; Maravilla, J. C.; Marks, A.; 401 Martins-Melo, F. R.; Martopullo, I.; Masoumi, S. Z.; Massano, J.; Massenburg, B. B.; 402 Mathur, M. R.; Maulik, P. K.; McAlinden, C.; McGrath, J. J.; McKee, M.; Mehndiratta, M. 403 M.; Mehri, F.; Mehta, K. M.; Meitei, W. B.; Memiah, P. T. N.; Mendoza, W.; Menezes, R. 404 G.; Mengesha, E. W.; Mengesha, M. B.; Mereke, A.; Meretoja, A.; Meretoja, T. J.; 405 Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Michalek, I. M.; Mihretie, K. M.; Miller, T. R.; 406 Mills, E. J.; Mirica, A.; Mirrakhimov, E. M.; Mirzaei, H.; Mirzaei, M.; Mirzaei-Alavijeh, M.; 407 Misganaw, A. T.; Mithra, P.; Moazen, B.; Moghadaszadeh, M.; Mohamadi, E.; Mohammad, 408 D. K.; Mohammad, Y.; Mohammad Gholi Mezerji, N.; Mohammadian-Hafshejani, A.; 409 Mohammadifard, N.; Mohammadpourhodki, R.; Mohammed, S.; Mokdad, A. H.; Molokhia, 410 M.; Momen, N. C.; Monasta, L.; Mondello, S.; Mooney, M. D.; Moosazadeh, M.; Moradi, G.; 411 Moradi, M.; Moradi-Lakeh, M.; Moradzadeh, R.; Moraga, P.; Morales, L.; Morawska, L.; 412 Moreno Velásquez, I.; Morgado-da-Costa, J.; Morrison, S. D.; Mosser, J. F.; Mouodi, S.; 413 Mousavi, S. M.; Mousavi Khaneghah, A.; Mueller, U. O.; Munro, S. B.; Muriithi, M. K.; 414 Musa, K. I.; Muthupandian, S.; Naderi, M.; Nagarajan, A. J.; Nagel, G.; Naghshtabrizi, B.; 415 Nair, S.; Nandi, A. K.; Nangia, V.; Nansseu, J. R.; Nayak, V. C.; Nazari, J.; Negoi, I.; Negoi, 416 R. I.; Netsere, H. B. N.; Ngunjiri, J. W.; Nguyen, C. T.; Nguyen, J.; Nguyen, M.; Nguyen, 417 M.; Nichols, E.; Nigatu, D.; Nigatu, Y. T.; Nikbakhsh, R.; Nixon, M. R.; Nnaji, C. A.; 418 Nomura, S.; Norrving, B.; Noubiap, J. J.; Nowak, C.; Nunez-Samudio, V.; Otoiu, A.; 419 Oancea, B.; Odell, C. M.; Ogbo, F. A.; Oh, I.-H.; Okunga, E. W.; Oladnabi, M.; Olagunju, A. 420 T.; Olusanya, B. O.; Olusanya, J. O.; Oluwasanu, M. M.; Omar Bali, A.; Omer, M. O.; Ong, 421 K. L.; Onwujekwe, O. E.; Orji, A. U.; Orpana, H. M.; Ortiz, A.; Ostroff, S. M.; Otstavnov, N.; 422 Otstavnov, S. S.; Øverland, S.; Owolabi, M. O.; P A, M.; Padubidri, J. R.; Pakhare, A. P.; 423 Palladino, R.: Pana, A.: Panda-Jonas, S.: Pandev, A.: Park, E.-K.: Parmar, P. G. K.: 424 Pasupula, D. K.; Patel, S. K.; Paternina-Caicedo, A. J.; Pathak, A.; Pathak, M.; Patten, S. 425 B.; Patton, G. C.; Paudel, D.; Pazoki Toroudi, H.; Peden, A. E.; Pennini, A.; Pepito, V. C. 426 F.; Peprah, E. K.; Pereira, A.; Pereira, D. M.; Perico, N.; Pham, H. Q.; Phillips, M. R.; 427 Pigott, D. M.; Pilgrim, T.; Pilz, T. M.; Pirsaheb, M.; Plana-Ripoll, O.; Plass, D.; Pokhrel, K. 428 N.; Polibin, R. V.; Polinder, S.; Polkinghorne, K. R.; Postma, M. J.; Pourjafar, H.; 429 Pourmalek, F.; Pourmirza Kalhori, R.; Pourshams, A.; Poznańska, A.; Prada, S. I.; 430 Prakash, V.; Pribadi, D. R. A.; Pupillo, E.; Quazi Syed, Z.; Rabiee, M.; Rabiee, N.; Radfar, 431 A.; Rafiee, A.; Rafiei, A.; Raggi, A.; Rahimi-Movaghar, A.; Rahman, M. A.; Rajabpour-432 Sanati, A.; Rajati, F.; Ramezanzadeh, K.; Ranabhat, C. L.; Rao, P. C.; Rao, S. J.; Rasella, 433 D.; Rastogi, P.; Rathi, P.; Rawaf, D. L.; Rawaf, S.; Rawal, L.; Razo, C.; Redford, S. B.; 434 Reiner, R. C., Jr; Reinig, N.; Reitsma, M. B.; Remuzzi, G.; Renjith, V.; Renzaho, A. M. N.; 435 Resnikoff, S.; Rezaei, N.; Rezai, M. sadegh; Rezapour, A.; Rhinehart, P.-A.; Riahi, S. M.; 436 Ribeiro, A. L. P.; Ribeiro, D. C.; Ribeiro, D.; Rickard, J.; Roberts, N. L. S.; Roberts, S.; 437 Robinson, S. R.; Roever, L.; Rolfe, S.; Ronfani, L.; Roshandel, G.; Roth, G. A.; Rubagotti, 438 E.; Rumisha, S. F.; Sabour, S.; Sachdev, P. S.; Saddik, B.; Sadeghi, E.; Sadeghi, M.; 439 Saeidi, S.; Safi, S.; Safiri, S.; Sagar, R.; Sahebkar, A.; Sahraian, M. A.; Sajadi, S. M.; 440 Salahshoor, M. R.; Salamati, P.; Salehi Zahabi, S.; Salem, H.; Salem, M. R. R.; 441 Salimzadeh, H.; Salomon, J. A.; Salz, I.; Samad, Z.; Samy, A. M.; Sanabria, J.; 442 Santomauro, D. F.; Santos, I. S.; Santos, J. V.; Santric-Milicevic, M. M.; Saraswathy, S. Y. 443 I.; Sarmiento-Suárez, R.; Sarrafzadegan, N.; Sartorius, B.; Sarveazad, A.; Sathian, B.; 444 Sathish, T.; Sattin, D.; Sbarra, A. N.; Schaeffer, L. E.; Schiavolin, S.; Schmidt, M. I.; 445 Schutte, A. E.; Schwebel, D. C.; Schwendicke, F.; Senbeta, A. M.; Senthilkumaran, S.; 446 Sepanlou, S. G.; Shackelford, K. A.; Shadid, J.; Shahabi, S.; Shaheen, A. A.; Shaikh, M. 447 A.; Shalash, A. S.; Shams-Beyranvand, M.; Shamsizadeh, M.; Shannawaz, M.; Sharafi, K.; 448 Sharara, F.; Sheena, B. S.; Sheikhtaheri, A.; Shetty, R. S.; Shibuya, K.; Shiferaw, W. S.; 449 Shiqematsu, M.; Shin, J. I.; Shiri, R.; Shirkoohi, R.; Shrime, M. G.; Shuval, K.; Siabani, S.;

450 Sigfusdottir, I. D.: Sigurvinsdottir, R.: Silva, J. P.: Simpson, K. E.: Singh, A.: Singh, J. A.: 451 Skiadaresi, E.; Skou, S. T.; Skryabin, V. Y.; Sobngwi, E.; Sokhan, A.; Soltani, S.; Sorensen, R. J. D.; Soriano, J. B.; Sorrie, M. B.; Soyiri, I. N.; Sreeramareddy, C. T.; 452 453 Stanaway, J. D.; Stark, B. A.; Stefan, S. C.; Stein, C.; Steiner, C.; Steiner, T. J.; Stokes, M. 454 A.; Stovner, L. J.; Stubbs, J. L.; Sudaryanto, A.; Sufiyan, M. B.; Sulo, G.; Sultan, I.; Sykes, 455 B. L.; Sylte, D. O.; Szócska, M.; Tabarés-Seisdedos, R.; Tabb, K. M.; Tadakamadla, S. K.; 456 Taherkhani, A.; Tajdini, M.; Takahashi, K.; Taveira, N.; Teagle, W. L.; Teame, H.; Tehrani-457 Banihashemi, A.; Teklehaimanot, B. F.; Terrason, S.; Tessema, Z. T.; Thankappan, K. R.; 458 Thomson, A. M.; Tohidinik, H. R.; Tonelli, M.; Topor-Madry, R.; Torre, A. E.; Touvier, M.; 459 Tovani-Palone, M. R. R.; Tran, B. X.; Travillian, R.; Troeger, C. E.; Truelsen, T. C.; Tsai, A. 460 C.; Tsatsakis, A.; Tudor Car, L.; Tyrovolas, S.; Uddin, R.; Ullah, S.; Undurraga, E. A.; 461 Unnikrishnan, B.; Vacante, M.; Vakilian, A.; Valdez, P. R.; Varughese, S.; Vasankari, T. J.; 462 Vasseghian, Y.; Venketasubramanian, N.; Violante, F. S.; Vlassov, V.; Vollset, S. E.; 463 Vongpradith, A.; Vukovic, A.; Vukovic, R.; Waheed, Y.; Walters, M. K.; Wang, J.; Wang, Y.; 464 Wang, Y.-P.; Ward, J. L.; Watson, A.; Wei, J.; Weintraub, R. G.; Weiss, D. J.; Weiss, J.; 465 Westerman, R.; Whisnant, J. L.; Whiteford, H. A.; Wiangkham, T.; Wiens, K. E.; Wijeratne, 466 T.; Wilner, L. B.; Wilson, S.; Wojtyniak, B.; Wolfe, C. D. A.; Wool, E. E.; Wu, A.-M.; Wulf 467 Hanson, S.; Wunrow, H. Y.; Xu, G.; Xu, R.; Yadgir, S.; Yahyazadeh Jabbari, S. H.; 468 Yamagishi, K.; Yaminfirooz, M.; Yano, Y.; Yaya, S.; Yazdi-Feyzabadi, V.; Yearwood, J. A.; 469 Yeheyis, T. Y.; Yeshitila, Y. G.; Yip, P.; Yonemoto, N.; Yoon, S.-J.; Yoosefi Lebni, J.; 470 Younis, M. Z.; Younker, T. P.; Yousefi, Z.; Yousefifard, M.; Yousefinezhadi, T.; Yousuf, A. 471 Y.; Yu, C.; Yusefzadeh, H.; Zahirian Moghadam, T.; Zaki, L.; Zaman, S. B.; Zamani, M.; 472 Zamanian, M.; Zandian, H.; Zangeneh, A.; Zastrozhin, M. S.; Zewdie, K. A.; Zhang, Y.; 473 Zhang, Z.-J.; Zhao, J. T.; Zhao, Y.; Zheng, P.; Zhou, M.; Ziapour, A.; Zimsen, S. R. M.; 474 Nachavi, M.: Murrav, C. J. L. Global Burden of 369 Diseases and Injuries in 204 Countries 475 and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 476 2019. The Lancet 2020, 396 (10258), 1204-1222. https://doi.org/10.1016/S0140-477 6736(20)30925-9. 478 Wang, H.; Bhutta, Z. A.; Coates, M. M.; Coggeshall, M.; Dandona, L.; Diallo, K.; Franca, E. (3) 479 B.; Fraser, M.; Fullman, N.; Gething, P. W.; Hay, S. I.; Kinfu, Y.; Kita, M.; Kulikoff, X. R.; 480 Larson, H. J.; Liang, J.; Liang, X.; Lim, S. S.; Lind, M.; Lopez, A. D.; Lozano, R.; Mensah, 481 G. A.; Mikesell, J. B.; Mokdad, A. H.; Mooney, M. D.; Naghavi, M.; Nguyen, G.; Rakovac, 482 I.; Salomon, J. A.; Silpakit, N.; Sligar, A.; Sorensen, R. J. D.; Vos, T.; Zhu, J.; Abajobir, A. 483 A.; Abate, K. H.; Abbas, K. M.; Abd-Allah, F.; Abdulle, A. M.; Abera, S. F.; Aboyans, V.; 484 Abraham, B.; Abubakar, I.; Abu-Raddad, L. J.; Abu-Rmeileh, N. M. E.; Abyu, G. Y.; Achoki, 485 T.; Adebiyi, A. O.; Adedeji, I. A.; Adelekan, A. L.; Adou, A. K.; Agarwal, A.; Ajala, O. N.; 486 Akinyemiju, T. F.; Akseer, N.; Alam, K.; Alam, N. K. M.; Alasfoor, D.; Aldridge, R. W.; 487 Alegretti, M. A.; Alemu, Z. A.; Ali, R.; Alkerwi, A.; Alla, F.; Al-Raddadi, R.; Alsharif, U.; 488 Altirkawi, K. A.; Martin, E. A.; Alvis-Guzman, N.; Amare, A. T.; Amberbir, A.; Amegah, A. 489 K.; Ameh, E. A.; Ammar, W.; Amrock, S. M.; Andersen, H. H.; Anderson, G. M.; Antonio, C. 490 A. T.; Ärnlöv, J.; Artaman, A.; Asayesh, H.; Asghar, R. J.; Assadi, R.; Atigue, S.; Avokpaho, 491 E. F. G. A.; Awasthi, A.; Quintanilla, B. P. A.; Bacha, U.; Badawi, A.; Balakrishnan, K.; 492 Baneriee, A.; Banigbe, B. F.; Barac, A.; Barber, R. M.; Barker-Collo, S. L.; Bärnighausen, 493 T.; Barrero, L. H.; Bayou, T. A.; Bayou, Y. T.; Bazargan-Hejazi, S.; Beardsley, J.; Bedi, N.; 494 Bekele, T.; Bell, M. L.; Bello, A. K.; Bennett, D. A.; Bensenor, I. M.; Berhane, A.; Bernabé, 495 E.; Betsu, B. D.; Beyene, A. S.; Bhatt, S.; Biadgilign, S.; Bikbov, B.; Birlik, S. M.; Bisanzio, 496 D.; Bjertness, E.; Blore, J. D.; Bourne, R. R. A.; Brainin, M.; Brazinova, A.; Breitborde, N. J. 497 K.; Brown, A.; Buckle, G. C.; Burch, M.; Butt, Z. A.; Campos-Nonato, I. R.; Campuzano, J. 498 C.; Cárdenas, R.; Carpenter, D. O.; Carrero, J. J.; Carter, A.; Casey, D. C.; Castañeda-499 Orjuela, C. A.; Rivas, J. C.; Castro, R. E.; Catalá-López, F.; Cercy, K.; Chang, H.-Y.; 500 Chang, J.-C.; Chibueze, C. E.; Chisumpa, V. H.; Choi, J.-Y. J.; Chowdhury, R.;

501 Christopher, D. J.; Ciobanu, L. G.; Colguhoun, S. M.; Cooper, C.; Cornaby, L.; Damtew, S. 502 A.; Danawi, H.; Dandona, R.; das Neves, J.; Davis, A. C.; de Jager, P.; De Leo, D.; 503 Degenhardt, L.; Deribe, K.; Deribew, A.; Jarlais, D. C. D.; deVeber, G. A.; Dharmaratne, S. D.; Dhillon, P. K.; Ding, E. L.; Doshi, P. P.; Doyle, K. E.; Duan, L.; Dubey, M.; Ebrahimi, H.; 504 505 Ellingsen, C. L.; Elyazar, I.; Endries, A. Y.; Ermakov, S. P.; Eshrati, B.; Esteghamati, A.; 506 Faraon, E. J. A.; Farid, T. A.; Farinha, C. S. e S.; Faro, A.; Farvid, M. S.; Farzadfar, F.; 507 Fereshtehnejad, S.-M.; Fernandes, J. C.; Fischer, F.; Fitchett, J. R. A.; Foigt, N.; Franklin, 508 R. C.; Friedman, J.; Fürst, T.; Gambashidze, K.; Gamkrelidze, A.; Ganguly, P.; Gebre, T.; 509 Gebrehiwot, T. T.; Gebremedhin, A. T.; Gebru, A. A.; Geleijnse, J. M.; Gessner, B. D.; 510 Ginawi, I. A. M.; Giref, A. Z.; Gishu, M. D.; Gomez-Dantes, H.; Gona, P.; Goodridge, A.; 511 Gopalani, S. V.; Goto, A.; Gouda, H. N.; Gugnani, H. C.; Guo, Y.; Gupta, R.; Gupta, R.; 512 Gupta, V.; Gyawali, B.; Haagsma, J. A.; Hafezi-Nejad, N.; Haile, D.; Hailu, A. D.; Hailu, G. 513 B.; Hamadeh, R. R.; Hamidi, S.; Hancock, J.; Handal, A. J.; Hankey, G. J.; Harb, H. L.; Harikrishnan, S.; Harun, K. M.; Havmoeller, R.; Hay, R. J.; Heredia-Pi, I. B.; Hoek, H. W.; 514 515 Horino, M.; Horita, N.; Hosgood, H. D.; Hotez, P. J.; Hoy, D. G.; Hsairi, M.; Hu, G.; Huang, 516 C.; Huang, J. J.; Huang, H.; Huiart, L.; Huynh, C.; Iburg, K. M.; Idrisov, B. T.; Innos, K.; 517 Jacobsen, K. H.; Jahanmehr, N.; Javanbakht, M.; Jayatilleke, A. U.; Jee, S. H.; Jeemon, 518 P.; Jha, V.; Jiang, G.; Jiang, Y.; Jibat, T.; Jin, Y.; Jonas, J. B.; Kabir, Z.; Kalkonde, Y.; 519 Kamal, R.; Kan, H.; Kang, G.; Karch, A.; Karema, C. K.; Kasaeian, A.; Kaul, A.; Kawakami, 520 N.; Kayibanda, J. F.; Kazanjan, K.; Keiyoro, P. N.; Kemp, A. H.; Kengne, A. P.; Keren, A.; 521 Kereselidze, M.; Kesavachandran, C. N.; Khader, Y. S.; Khalil, I. A.; Khan, A. R.; Khan, E. A.; Khang, Y.-H.; Khonelidze, I.; Khubchandani, J.; Kim, C.; Kim, D.; Kim, Y. J.; Kissoon, 522 523 N.; Kivipelto, M.; Knibbs, L. D.; Kokubo, Y.; Kosen, S.; Koul, P. A.; Koyanagi, A.; Defo, B. 524 K.; Bicer, B. K.; Kudom, A. A.; Kumar, G. A.; Kutz, M. J.; Kyu, H. H.; Lal, D. K.; Lalloo, R.; 525 Lam, H.: Lam, J. O.: Lansingh, V. C.: Larsson, A.: Leigh, J.: Leung, R.: Li, Y.: Li, Y.: 526 Lindsay, M. P.; Liu, P. Y.; Liu, S.; Lloyd, B. K.; Lo, W. D.; Logroscino, G.; Low, N.; 527 Lunevicius, R.; Lyons, R. A.; Ma, S.; Razek, H. M. A. E.; Razek, M. M. A. E.; Mahdavi, M.; 528 Majdan, M.; Majeed, A.; Malekzadeh, R.; Mapoma, C. C.; Marcenes, W.; Martinez-Raga, J.; Marzan, M. B.; Masiye, F.; McGrath, J. J.; Meaney, P. A.; Mehari, A.; Mehndiratta, M. 529 530 M.; Mekonnen, A. B.; Melaku, Y. A.; Memiah, P.; Memish, Z. A.; Mendoza, W.; Meretoja, 531 A.; Meretoja, T. J.; Mhimbira, F. A.; Miller, T. R.; Mills, E. J.; Mirarefin, M.; Misganaw, A.; 532 Mock, C. N.; Mohammad, K. A.; Mohammadi, A.; Mohammed, S.; Monasta, L.; Hernandez, 533 J. C. M.; Montico, M.; Moore, A. R.; Moradi-Lakeh, M.; Morawska, L.; Mori, R.; Mueller, U. 534 O.; Murphy, G. A. V.; Murthy, S.; Nachega, J. B.; Naheed, A.; Naidoo, K. S.; Naldi, L.; Nand, D.; Nangia, V.; Neupane, S.; Newton, C. R.; Newton, J. N.; Ng, M.; Ngalesoni, F. N.; 535 536 Nguhiu, P.; Nguyen, Q. L.; Nisar, M. I.; Pete, P. M. N.; Norheim, O. F.; Norman, R. E.; 537 Ogbo, F. A.; Oh, I.-H.; Ojelabi, F. A.; Olivares, P. R.; Olusanya, B. O.; Olusanya, J. O.; 538 Oren, E.; Ota, E.; PA, M.; Park, E.-K.; Park, H.-Y.; Parsaeian, M.; Caicedo, A. J. P.; Patten, 539 S. B.; Pedro, J. M.; Pereira, D. M.; Perico, N.; Pesudovs, K.; Petzold, M.; Phillips, M. R.; 540 Pillay, J. D.; Pishgar, F.; Polinder, S.; Pope, D.; Popova, S.; Pourmalek, F.; Qorbani, M.; 541 Rabiee, R. H. S.; Rafay, A.; Rahimi-Movaghar, V.; Rahman, M.; Rahman, M. H. U.; 542 Rahman, S. U.; Rai, R. K.; Raju, M.; Ram, U.; Rana, S. M.; Ranabhat, C. L.; Rao, P.; 543 Refaat, A. H.; Remuzzi, G.; Resnikoff, S.; Reynolds, A.; Rojas-Rueda, D.; Ronfani, L.; 544 Roshandel, G.; Roth, G. A.; Roy, A.; Ruhago, G. M.; Sagar, R.; Saleh, M. M.; Sanabria, J. 545 R.; Sanchez-Niño, M. D.; Santos, I. S.; Santos, J. V.; Sarmiento-Suarez, R.; Sartorius, B.; 546 Satpathy, M.; Savic, M.; Sawhney, M.; Schneider, I. J. C.; Schöttker, B.; Schwebel, D. C.; 547 Seedat, S.; Sepanlou, S. G.; Servan-Mori, E. E.; Setegn, T.; Shahraz, S.; Shaikh, M. A.; Shakh-Nazarova, M.; Sharma, R.; She, J.; Sheikhbahaei, S.; Shen, J.; Sheth, K. N.; 548 549 Shibuya, K.; Shin, H. H.; Shin, M.-J.; Shiri, R.; Shuie, I.; Sigfusdottir, I. D.; Silva, D. A. S.; 550 Silverberg, J.; Simard, E. P.; Sindi, S.; Singh, A.; Singh, J. A.; Singh, O. P.; Singh, P. K.; 551 Singh, V.; Soriano, J. B.; Soshnikov, S.; Sposato, L. A.; Sreeramareddy, C. T.;

| 552 | | Stathopoulou, V.; Steel, N.; Stroumpoulis, K.; Sturua, L.; Sunguya, B. F.; Swaminathan, S.; |
|------------|---------------------|---|
| 553 | | Sykes, B. L.; Szoeke, C. E. I.; Tabarés-Seisdedos, R.; Tavakkoli, M.; Taye, B.; Tedla, B. |
| 554 | | A.; Tefera, W. M.; Tekle, T.; Shifa, G. T.; Terkawi, A. S.; Tesfay, F. H.; Tessema, G. A.; |
| 555 | | Thapa, K.; Thomson, A. J.; Thorne-Lyman, A. L.; Tobe-Gai, R.; Tonelli, M.; Topor-Madry, |
| 556 | | R.; Topouzis, F.; Tran, B. X.; Troeger, C.; Truelsen, T.; Dimbuene, Z. T.; Tura, A. K.; |
| 557 | | Tyrovolas, S.; Ukwaja, K. N.; Uneke, C. J.; Uthman, O. A.; Vaezghasemi, M.; Vasankari, |
| 558 | | T.; Vasconcelos, A. M. N.; Venketasubramanian, N.; Verma, R. K.; Violante, F. S.; |
| 559 | | Vladimirov, S. K.: Vlassov, V. V.: Vollset, S. E.: Wang, L.: Wang, Y.: Weichenthal, S.: |
| 560 | | Weidernass F Weintraub R G Weiss D J Werdecker A Westerman R |
| 561 | | Widdowson M-A Wijerathe T Williams T N Wivsonge C S Wolfe C D A Wolfe |
| 562 | | I: Won S: Wubshet M: Xiao O: Xu G: Yaday A K: Yakob B: Yano Y: Yaseri M: |
| 563 | | Vo D: Volvo H. C: Vin D: Vonometo N: Voon S. L: Vounis M. 7: Vu C: Zeidi 7: |
| 564 | | Zaki M E S : Zoob H : Zhong H : Zhong V : Zhong V : Zhong M : Zodnov S : Murrov C |
| 504 | | Zaki, W. E. S., Zeeb, H., Zhang, H., Zhao, Y., Zheng, Y., Zhou, W., Zoupey, S., Wullay, C. |
| 505 | | J. L. Global, Regional, National, and Selected Subnational Levels of Stillbirths, Neonatal, |
| 566 | | Infant, and under-5 Mortality, 1980–2015: A Systematic Analysis for the Global Burden of |
| 567 | | Disease Study 2015. The Lancet 2016 , 388 (10053), 1725–1774. |
| 568 | | https://doi.org/10.1016/S0140-6736(16)31575-6. |
| 569 | (4) | Killerby, M. E.; Biggs, H. M.; Haynes, A.; Dahl, R. M.; Mustaquim, D.; Gerber, S. I.; |
| 570 | | Watson, J. T. Human Coronavirus Circulation in the United States 2014–2017. <i>Journal of</i> |
| 571 | | <i>Clinical Virology</i> 2018 , <i>101</i> , 52–56. https://doi.org/10.1016/j.jcv.2018.01.019. |
| 572 | (5) | Olsen, S. J.; Winn, A. K.; Budd, A. P.; Prill, M. M.; Steel, J.; Midgley, C. M.; Kniss, K.; |
| 573 | | Burns, E.; Rowe, T.; Foust, A.; Jasso, G.; Merced-Morales, A.; Davis, C. T.; Jang, Y.; |
| 574 | | Jones, J.; Daly, P.; Gubareva, L.; Barnes, J.; Kondor, R.; Sessions, W.; Smith, C.; |
| 575 | | Wentworth, D. E.; Garg, S.; Havers, F. P.; Fry, A. M.; Hall, A. J.; Brammer, L.; Silk, B. J. |
| 576 | | Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic |
| 577 | | - United States, 2020-2021. MMWR Morb Mortal Wkly Rep 2021, 70 (29), 1013–1019. |
| 578 | | https://doi.org/10.15585/mmwr.mm7029a1. |
| 579 | (6) | Chow, E. J.; Uveki, T. M.; Chu, H. Y. The Effects of the COVID-19 Pandemic on |
| 580 | (-) | Community Respiratory Virus Activity, Nature Reviews Microbiology 2023, 21 (3), 195– |
| 581 | | 210 https://doi.org/10.1038/s41579-022-00807-9 |
| 582 | (7) | Boehm A B Hughes B Duong D Chan-Herur V Buchman A Wolfe M K White |
| 583 | (,) | B. J. Wastewater Concentrations of Human Influenza, Metanneumovirus, Parainfluenza |
| 584 | | Respiratory Syncytial Virus, Rhinovirus, and Seasonal Coronavirus Nucleic-Acids during |
| 585 | | the COVID-19 Pandemic: A Surveillance Study. The Lancet Microbe 2023 |
| 586 | | https://doi.org/10.1016/S2666.52/7/22)00386.X |
| 500 | (0) | Hamid S: Winn A: Darikh D: Janas J: McMarrow M: Drill M: Silk D. J. Scobia H |
| 507 | (0) | M: Holl A. J. Socoonality of Doppiratory Synautic Virus – United States 2017, 2022 |
| 500 | | MMMM Morth Morthel M/My Day 2022, 72, 255, 264 |
| 009 500 | | MMWWR MOID MOILAI WKIY REP 2023, 72, 335-301. |
| 590 | $\langle 0 \rangle$ | http://dx.doi.org/10.15585/mmwr.mm/214a1. |
| 591 | (9) | Furlow, B. Triple-Demic Overwhelms Paediatric Units in US Hospitals. The Lancet Child & |
| 592 | | Adolescent Health 2023, 7 (2), 86. https://doi.org/10.1016/S2352-4642(22)00372-8. |
| 593 | (10) | Weixel, N. 'Tripledemic' Infected Nearly 40 Percent of Households, Survey Finds. <i>The Hill</i> . |
| 594 | | February 7, 2023. https://thehill.com/policy/healthcare/3846161-tripledemic-infected- |
| 595 | | nearly-40-percent-of-households-survey-finds/ (accessed 2023-05-22). |
| 596 | (11) | Chow, Y. P.; Chin, B. H. Z.; Loo, J. M.; Moorthy, L. R.; Jairaman, J.; Tan, L. H.; Tay, W. W. |
| 597 | | Y. Clinical and Epidemiological Characteristics of Patients Seeking COVID-19 Testing in a |
| 598 | | Private Centre in Malaysia: Is There a Role for Private Healthcare in Battling the |
| 599 | | Outbreak? PLOS ONE 2021, 16 (10), e0258671. |
| 600 | | https://doi.org/10.1371/journal.pone.0258671. |
| 601 | (12) | Radar, B.; Gertz, A.; Iuliano, A. D.: Gilmer, M.: Wronski, L.: Astlev, C. M.: Sewalk, K.: |
| 602 | () | Varrelman, T.; Cohen, J.; Parikh, R.; Reese, H. F.; Reed, C.; Brownstein, J. S. Use of At- |
| | | |

603 Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022, MMWR Morb 604 Mortal Wkly Rep 2022, 71, 489–494. http://dx.doi.org/10.15585/mmwr.mm7113e1. 605 (13) McElfish, P. A.; Purvis, R.; James, L. P.; Willis, D. E.; Andersen, J. A. Perceived Barriers to 606 COVID-19 Testing. International Journal of Environmental Research and Public Health 607 2021, 18 (5). https://doi.org/10.3390/ijerph18052278. 608 (14) Jajosky, R. A.; Groseclose, S. L. Evaluation of Reporting Timeliness of Public Health 609 Surveillance Systems for Infectious Diseases. BMC Public Health 2004, 4 (1), 29. 610 https://doi.org/10.1186/1471-2458-4-29. 611 (15) Simonsen, L.; Gog, J. R.; Olson, D.; Viboud, C. Infectious Disease Surveillance in the Big 612 Data Era: Towards Faster and Locally Relevant Systems. The Journal of Infectious 613 Diseases 2016, 214 (suppl 4), S380–S385. https://doi.org/10.1093/infdis/jiw376. 614 (16) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.; Balliet, 615 M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput 616 Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned 617 Treatment Works in Northern California Shows Strong Association with COVID-19 618 Incidence. mSystems 2021, 6 (5), e00829-21. https://doi.org/10.1128/mSystems.00829-21. 619 (17) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput Pre-Analytical 620 Processing of Wastewater Settled Solids for SARS-CoV-2 RNA Analyses. protocols.io 621 2021. 622 (18) Topol, A.; Wolfe, M.; Wigginton, K.; White, B.; Boehm, A. High Throughput RNA Extraction 623 and PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of SARS-CoV-2 624 RNA. protocols.io 2021. 625 (19) Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez-Cassi, X.; Ganesanandamoorthy, P.; Kull, 626 A.; Scheidegger, A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol, A.; 627 Wigginton, K. R.: Wolfe, M. K.: Kohn, T.: Ort, C.: Stadler, T.: Julian, T. R. Wastewater-628 Based Estimation of the Effective Reproductive Number of SARS-CoV-2. Environmental 629 Health Perspectives 2022, 130 (5), 057011-1. 630 (20) Symonds, E. M.; Nguyen, K. H.; Harwood, V. J.; Breitbart, M. Pepper Mild Mottle Virus: A 631 Plant Pathogen with a Greater Purpose in (Waste)Water Treatment Development and 632 Public Health Management. Water Research 2018, 144, 1–12. 633 https://doi.org/10.1016/j.watres.2018.06.066. 634 (21) Simpson, A.; Topol, A.; White, B.; Wolfe, M. K.; Wigginton, K.; Boehm, A. B. Effect of 635 Storage Conditions on SARS-CoV-2 RNA Quantification in Wastewater Solids. PeerJ 636 **2021**, 9, e11933. https://doi.org/10.7717/peeri.11933. 637 (22) California Influenza Surveillance Program. Influenza and Other Respiratory Viruses 638 Weekly Report; 2023. 639 https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunizat 640 ion/Week2021-2245 FINALReport.pdf (accessed 2023-06-08). 641 (23) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong; 642 Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations 643 in Wastewater Solids from Central and Coastal California, USA. Scientific Data 2023, 644 Accepted. 645 (24) Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T. 646 The Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and 647 DPCR Quality and Reporting for Environmental Microbiology. Environ. Sci. Technol. 2021, 648 55 (15), 10210–10223. https://doi.org/10.1021/acs.est.1c01767. 649 (25) van den Hoogen, B. G.; de Jong, J. C.; Groen, J.; Kuiken, T.; de Groot, R.; Fouchier, R. A.; 650 Osterhaus, A. D. A Newly Discovered Human Pneumovirus Isolated from Young Children 651 with Respiratory Tract Disease. Nat Med 2001, 7 (6), 719-724. 652 https://doi.org/10.1038/89098. 653 (26) VAN DEN HOOGEN, B. G.; OSTERHAUS, D. M. E.; FOUCHIER, R. A. M. Clinical Impact

- and Diagnosis of Human Metapneumovirus Infection. *The Pediatric Infectious Disease Journal* 2004, 23 (1).
- (27) Edwards, K. M.; Zhu, Y.; Griffin, M. R.; Weinberg, G. A.; Hall, C. B.; Szilagyi, P. G.; Staat,
 M. A.; Iwane, M.; Prill, M. M.; Williams, J. V. Burden of Human Metapneumovirus Infection
 in Young Children. *N Engl J Med* 2013, *368* (7), 633–643.
- 659 https://doi.org/10.1056/NEJMoa1204630.
- (28) Wei, C.-J.; Crank, M. C.; Shiver, J.; Graham, B. S.; Mascola, J. R.; Nabel, G. J. NextGeneration Influenza Vaccines: Opportunities and Challenges. *Nature Reviews Drug Discovery* 2020, *19* (4), 239–252. https://doi.org/10.1038/s41573-019-0056-x.
- (29) Mejias, A.; Rodríguez-Fernández, R.; Oliva, S.; Peeples, M. E.; Ramilo, O. The Journey to
 a Respiratory Syncytial Virus Vaccine. *Annals of Allergy, Asthma & Immunology* 2020, 125
 (1), 36–46. https://doi.org/10.1016/j.anai.2020.03.017.
- (30) US FDA. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine.
 https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory syncytial-virus-rsv-vaccine (accessed 2023-06-08).
- 669 (31) Center for Disease Control. Human metapneumovirus. https://www.cdc.gov/ncird/human-670 metapneumovirus.html (accessed 2023-05-23).
- (32) Li, Y.; Reeves, R. M.; Wang, X.; Bassat, Q.; Brooks, W. A.; Cohen, C.; Moore, D. P.;
 Nunes, M.; Rath, B.; Campbell, H.; Nair, H.; Acacio, S.; Alonso, W. J.; Antonio, M.; Ayora
 Talavera, G.; Badarch, D.; Baillie, V. L.; Barrera-Badillo, G.; Bigogo, G.; Broor, S.; Bruden,
 D.; Buchy, P.; Byass, P.; Chipeta, J.; Clara, W.; Dang, D.-A.; de Freitas Lázaro Emediato,
 C. C.; de Jong, M.; Díaz-Quiñonez, J. A.; Do, L. A. H.; Fasce, R. A.; Feng, L.; Ferson, M.
 J.; Gentile, A.; Gessner, B. D.; Goswami, D.; Goyet, S.; Grijalva, C. G.; Halasa, N.;
 Hellferscee, O.; Hessong, D.; Homaira, N.; Jara, J.; Kahn, K.; Khuri-Bulos, N.; Kotloff, K.
- Hellferscee, O.; Hessong, D.; Homaira, N.; Jara, J.; Kahn, K.; Khuri-Bulos, N.; Kotloff, K.
 L.: Lanata, C. F.; Lopez, O.; Lopez Bolaños, M. R.; Lucero, M. G.; Lucion, F.; Lupisan, S.
- 679 P.; Madhi, S. A.; Mekgoe, O.; Moraleda, C.; Moyes, J.; Mulholland, K.; Munywoki, P. K.;
- Naby, F.; Nguyen, T. H.; Nicol, M. P.; Nokes, D. J.; Noyola, D. E.; Onozuka, D.; Palani, N.;
- 681 Poovorawan, Y.; Rahman, M.; Ramaekers, K.; Romero, C.; Schlaudecker, E. P.;
- Schweiger, B.; Seidenberg, P.; Simoes, E. A. F.; Singleton, R.; Sistla, S.; Sturm-Ramirez,
 K.; Suntronwong, N.; Sutanto, A.; Tapia, M. D.; Thamthitiwat, S.; Thongpan, I.;
- Tillekeratne, G.; Tinoco, Y. O.; Treurnicht, F. K.; Turner, C.; Turner, P.; van Doorn, R.; Van
 Ranst, M.; Visseaux, B.; Waicharoen, S.; Wang, J.; Yoshida, L.-M.; Zar, H. J. Global
 Patterns in Monthly Activity of Influenza Virus, Respiratory Syncytial Virus, Parainfluenza
 Virus, and Metapneumovirus: A Systematic Analysis. *The Lancet Global Health* **2019**, 7
 (8), e1031–e1045. https://doi.org/10.1016/S2214-109X(19)30264-5.
- (3) Boehm, A. B.; Wolfe, M. K.; White, B. J.; Hughes, B.; Duong, D. Divergence of Wastewater
 SARS-CoV-2 and Reported Laboratory-Confirmed COVID-19 Incident Case Data
 Coincident with Wide-Spread Availability of at-Home COVID-19 Antigen Tests. *PeerJ* 2023, Accepted.
- (34) Wolfe, M. K.; Yu, A. T.; Duong, D.; Rane, M. S.; Hughes, B.; Chan-Herur, V.; Donnelly, M.;
 Chai, S.; White, B. J.; Vugia, D. J.; Boehm, A. B. Use of Wastewater for Mpox Outbreak
 Surveillance in California. *N Engl J Med* 2023. https://doi.org/10.1056/NEJMc2213882.
- 696 697
- 698
- 699
- 700
- 701
- 702
- 703

- 704
- 705

Table 1. Date of onset and offset, as well as peak of wastewater events for each human viral

target measured in wastewater solids for each of 8 POTWs. A "?" indicates that the offset had

not yet occurred during the study period. Dates for two events are provided if two wastewater

ros events were identified. SC2 is SARS-CoV-2, only the peak is provided for SC2.

| POTW | HMPV | | IAV | | RSV | | SC2 |
|-------|-----------------------------------|----------|--------------------------------------|-----------|-----------------------|--------|--------|
| | onset/offset | peak | onset/offset | peak | onset/offset | peak | peak |
| Gil | 3 Dec - ? | 3 Jan | 13 Nov - 25 Jan | 30 Nov | 24 Oct - 20 Mar | 30 Nov | 1 Dec |
| SJ | 30 Oct - ? | 22 March | 14 July - 23 July 8 Nov - 3 Mar | 30 Nov | 17 Sept - 18 April | 20 Dec | 1 Dec |
| PA | 1 Nov - ? | 26 Nov | 14 July - 21 Sept 11 Nov - 13 Feb | 26 Nov | 11 Oct - 2 April | 25 Nov | 30 Nov |
| SVCW | 12 Nov - ? | 6 Dec | 4 Nov - 24 Feb | 9 Dec | 23 Sept - 25 April | 13 Dec | 4 Mar |
| SE | 1 Sept - 24 Sept 13 Oct - ? | 1 April | 26 Oct - 25 Feb | 8 Dec | 6 Oct - 25 Mar | 29 Nov | 5 Jan |
| Ocean | 6 Aug - ? | 30 March | 18 Nov - 22 Feb | 13 Dec | 23 Sept - 17 April | 4 Dec | 16 Mar |
| SAC | 10 Nov - ? | 13 March | 4 Nov - 30 Jan | 24 Nov | 19 Oct - 27 Mar | 14 Dec | 7 Dec |
| Sun | 4 Nov - ? | 2 March | 10 Nov - 1 Mar | 2 Dec | 26 Sept - 29 April | 3 Dec | 9 Feb |



SARS-CoV-2 RSV IAV HMPV



- 713 PMMoV in wastewater solids at eight POTWs between 7/1/22 and 5/7/23; the ratio is unitless.
- Raw data are shown as filled circles, lines are 5-d trimmed averages. Note the difference in
 scale between the SARS-CoV-2 (upper left axis of each panel) and the other viruses (lower left
- axis of each panel). The acronym for each POTW is provided in the upper left corner.
- 717

| 1 | Supporting information for |
|----------|--|
| 2 | |
| 3 4 | Community occurrence of metapneumovirus, influenza A, and respiratory syncytial virus (RSV) inferred from wastewater solids during the winter 2022-2023 tripledemic |
| 5 | |
| 6 | Authors |
| 7 8 | Alexandria B. Boehm ^{1*} , Marlene K. Wolfe ² , Bradley White ³ , Bridgette Hughes ³ , Dorothea Duong ³ , Amanda Bidwell ¹ |
| 9 | |
| 10 | |
| 11 | Affiliations |
| 12 13 | 1. Department of Civil & Environmental Engineering, School of Engineering and Doerr School of Sustainability, Stanford University, Stanford, CA, USA |
| 14 | 2. Gangarosa Department of Environmental Health. Rollins School of Public Health. Emory |
| 15 | University, Atlanta, GA, USA |
| 16 | 3. Verily Life Sciences, South San Francisco, CA, USA |
| 17 | |
| 18 | |
| 19 | |
| 20 | *corresponding author: Alexandria Boehm (aboehm@stanford.edu) |
| 21 | |
| 22 | |
| 23 | |
| 24 | Number of pages: 13 |
| 25 | Number of Tables: 3 |
| 26 | Number of Figures: 6 |
| 27 | |
| 28 | |
| 29 | |
| 30 | |

31

32

Additional details of sample collection. At seven of the eight POTWs, settled solids were collected from the primary clarifier. Settled solids samples were grab samples except for at SJ where staff collected a 24-h composite sample¹. At Gil, solids were settled from a 24-h

- 36 composite influent sample using standard method 160.5^2 .
- 37

38 Additional details of sample processing and nucleic-acid extraction. Briefly, solids were

39 dewatered by centrifugation, and an aliquot of dewatered solids was dried to determine its dry

- 40 weight, and another aliquot was resuspended in the bovine coronavirus (BCoV)-spiked
- 41 DNA/RNA shield (Zymo Research) at a concentration of 75 mg/ml. Bovine coronavirus (BCoV)
- 42 was used as a positive recovery control. This concentration of solids was chosen as previous
- 43 work titrated solutions with various concentrations of solids to identify a concentration that
- 44 minimized inhibition while maintaining sensitivity of the assays^{3,4}. The suspension was
- homogenized, and then centrifuged. The supernatant was subjected to nucleic acid extraction.

Additional details of digital droplet RT-PCR. Digital droplet PCR was performed on 20-µl
samples from a 22-µl reaction volume, prepared using 5.5-µl template, mixed with 5.5 µl of OneStep RT-ddPCR Advanced kit for Probes (catalog no. 1863021; Bio-Rad), 2.2 µl reverse

- 50 transcriptase, 1.1 µl dithiothreitol (DTT), and primers and probes at a final concentration of
- 51 900 nM and 250 nM, respectively. Droplets were generated using the AutoDG Automated
- 52 Droplet Generator (Bio-Rad). PCR was performed using Mastercycler Pro with the following
- 53 protocol: reverse transcription at 50°C for 60 min, enzyme activation at 95°C for 5 min, 40
- 54 cycles with 1 cycle consisting of denaturation at 95°C for 30 s and annealing and extension at
- 55 either 59°C or 61°C (for human viruses) or 56°C (for PMMoV/BCoV duplex assay) for 30 s,
- 56 enzyme deactivation at 98°C for 10 min, and then an indefinite hold at 4°C. The ramp rate for
- 57 temperature changes was set at 2°C/s, and the final hold at 4°C was performed for a minimum
- 58 of 30 min to allow the droplets to stabilize.
- 59

60 All samples were processed for HMPV in multiplex as described in the Data Descriptor by

- 61 Boehm et al.⁴. For the remaining human viral assay, samples collected between 7/1/22 and
- 62 3/11/23, were processed in multiplex as described in the Data Descriptor by Boehm et al.⁴
- 63 Thereafter, for all samples collected between 3/12/23 and 5/7/23 (month/day/year format),
- 64 assays for SARS-CoV-2 N gene (FAM), RSV (Cy5), and IAV (Cy5.5) were multiplexed using the
- 65 probe mixing method; the multiplex assay also contained assays for influenza B and norovirus
- 66 GII for which results are not presented herein. This assay was run at an annealing temperature
- 67 of 61°C. BCoV and PMMoV were run in a duplex assay.
- 68
- 69 Each sample was run in 10 replicate wells. On each 96 well plate, extraction-negative controls
- 70 were run in 3 wells, and extraction-positive controls in 1 well. PCR-positive controls of SARS-
- 71 CoV-2, IAV, RSV, HMPV, BCoV, and PMMoV were run in 1 well, and no-template controls
- 72 (NTC) were run in 3 wells. Positive controls consisted of BCoV and PMMoV gene block controls
- and the same human virus controls described in the main text as positive extraction controls.
- 74 Results from replicate wells were merged for analysis.

75

| 76 | Droplets were analyzed using the QX200 or QX600 Droplet Reader (Bio-Rad). Each sample |
|----------------------------------|--|
| 77 | was run in 10 replicate wells on 96 well plates that also contained positive and negative |
| 78 | extraction and PCR controls (see SI). Thresholding was done using QuantaSoft Analysis Pro |
| 79 | software (Bio-Rad, version 1.0.596). In order for a sample to be recorded as positive, it had to |
| 80 | have at least three positive droplets. Three positive droplets corresponds to a concentration |
| 81 | between ~500 and 1000 copies (cp)/g dry weight; the range in values is a result of the range in |
| 82 | the equivalent mass of dry solids added to the wells. Any plates for which negative controls |
| 83 | were positive or positive controls were negative were discarded and the samples re-processed |
| 84 | and rerun. |
| 85 | |
| 86 87 88 89 90 91 | IAV subtype assay design and testing. To design the primers and probes, influenza A genome sequences were downloaded from NCBI in January 2023 and aligned to identify conserved regions in the specified regions of the genome. Then primers and probes targeting those conserved regions were developed in silico using Primer3Plus (<u>https://primer3plus.com/</u>) (Table S2). |
| 92 93 94 95 96 | Primers and probes were then screened for specificity in silico, and in vitro against other respiratory and enteric viruses. including adenoviruses, coronaviruses, metapneumovirus, parainfluenza, RSV, coxsackievirus, echovirus, parechovirus (NATtrol Respiratory Verification Panel NATRVP2.1-BIO and NATtrol EV Panel NATEVP-C viral panels, Zeptometrix, Buffalo, NY), as well as synthetic genomic RNA from influenza A H1N1 and influenza A H3N2 (Twist |

- 97 Bioscience, South San Francisco, CA).
- 98

99 Measuring IAV subtype markers in wastewater solids. RNA extracts from the two POTWs 100 (SJ and Ocean) were stored at -80°C for 1-5 months. RNA was subjected to a single freeze-101 thaw and used as template undiluted in digital droplet PCR using the same methods outlined 102 above. Assays were run in multiplex using the probe mixing approach. H1 and N1 were 103 multiplexed in the HEX and Cy5.5 channels, respectively. H3, N2, and IAV were multiplexed in 104 the HEX, FAM/HEX, and ROX channels. Ten replicates were run for each sample, for each 105 sample with the same number of positive and negative extraction and PCR controls per plate as 106 described for the prospective measurements described in the main text. Positive controls 107 consisted of synthetic genomic RNA from influenza H1N1 and H3N2 (Twist). Results are 108 reported as copies per gram dry weight.

109

110 Correlations between wastewater and clinical positivity rates. IAV in wastewater solids 111 was significantly associated with state-aggregated weekly clinical specimen influenza positivity 112 rates at all POTWs (tau between 0.54 and 0.73, all $p<10^{-6}$) except for SVCW and Sun where the 113 association was not statistically significant. Weekly median normalized RSV in wastewater 114 solids was significantly associated with state-aggregated weekly clinical specimen RSV

- positivity rates at all plants (tau between 0.59 and 0.67, all $p<10^{-7}$). Weekly median normalized
- 116 HMPV in wastewater solids was significantly associated with state-aggregated weekly clinical
- 117 specimen HMPV positivity rates at all plants (tau between 0.52 and 0.72, p<10⁻⁶). Daily
- 118 normalized SARS-CoV-2 was positively associated with daily state-aggregated COVID-19
- positivity rates (tau between 0.27 and 0.48, all $p < 10^{-11}$), as has been shown extensively in
- 120 previous work.^{1,5}
- 121

122 **References**

- 123
- (1) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.; Balliet,
 M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput
 Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned
 Treatment Works in Northern California Shows Strong Association with COVID-19
 Incidence. *mSystems* 2021, 6 (5), e00829-21. https://doi.org/10.1128/mSystems.00829-21.
- (2) AWWA. Standard Methods for the Examination of Water and Wastewater, 21st ed.; Eaton,
 A. D., Clesceri, L. S., Rice, E. W., Greenberg, A. E., Series Eds.; American Public Health
 Association, American Water Works Association, Water Environment Federation: Baltimore,
 2005.
- (3) Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez-Cassi, X.; Ganesanandamoorthy, P.; Kull,
 A.; Scheidegger, A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol, A.;
 Wigginton, K. R.; Wolfe, M. K.; Kohn, T.; Ort, C.; Stadler, T.; Julian, T. R. WastewaterBased Estimation of the Effective Reproductive Number of SARS-CoV-2. *Environmental Health Perspectives* 2022, *130* (5), 057011–1.
- (4) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong;
 Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations in Wastewater Solids from Central and Coastal California, USA. *Scientific Data* 2023, Accepted.
- (5) Duvallet, C.; Wu, F.; McElroy, K. A.; Imakaev, M.; Endo, N.; Xiao, A.; Zhang, J.; Floyd-O'Sullivan, R.; Powell, M. M.; Mendola, S.; Wilson, S. T.; Cruz, F.; Melman, T.; Sathyanarayana, C. L.; Olesen, S. W.; Erickson, T. B.; Ghaeli, N.; Chai, P.; Alm, E. J.; Matus, M. Nationwide Trends in COVID-19 Cases and SARS-CoV-2 RNA Wastewater Concentrations in the United States. *ACS EST Water* **2022**, *2* (11), 1899–1909. https://doi.org/10.1021/acsestwater.1c00434.
- (6) Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T. The
 Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and DPCR
- 150 Quality and Reporting for Environmental Microbiology. *Environ. Sci. Technol.* **2021**, 55 (15),
- 151 10210–10223. https://doi.org/10.1021/acs.est.1c01767.
- 152



157 Figure S1. Map of sewersheds participating in the study.

159

Environmental Microbiology Minimum Information Checklist

| Study Description Study: SCAN Date: March 2023 Completed by: Alexandria Boehm | | Sample Nucleic Action Reduction Extraction Contribution was used, as deported in the Data Descriptor. Methods powded in the Data Descriptor. | Person PCR Detection Analysis Transactipation □ qPCR 圖 dPCR No formal analysis One Step RT-PCR All rethods provided including the dolling (deciditie) No formal analysis mad done in this project |
|--|--|--|--|
| Control Checklist Step performed Step has control info & control replicate Control introduced Internal/External Independent/Parallel Step has control info # control replicate Control result reported Data Handling reported | Environmental Sample Sampling Treatment | Sample Reduction | Reverse Transcription PCR Detection Image: Construction of the second |
| Process Checc Environmental Sampling Sampling Procedure Number of samples Sample amount, mean, range Sample deaters, dates, times Sample Treatment Performed Treatment procedure Reagents | klist Sample Reduction Performed Reduction procedure Reagents Concentration Factor Nucleic Acid Extraction Extraction procedure Amount extracted, amount obtained Extract storage conditions | qPCR or dPCR Target gene name, amplicolength Thermocycling temperature and times Master mix: composition, vendors, concentrations Additives: vendors, concentrations Additives: vendors, concentrations Template amount added, pre-treatment (if any) Primers: sequences, concentrations, vendors, references | an Amplicon confirmation method (probe, melt curve, etc) Probe sequence, concentration, vendor, reference Instrumentation Equivalent volume of sample analyzed by PCR Inhibition assessment procedure Inhibition control description (if used) Number samples tested and found inhibited |
| Reverse Transcription Performed One or two step CDNA storage conditions (if two step) | | Analysis – dPCR Threshold settings Technical replicates, number well merging Partitions measured, numb | Analysis – qPCR Method for handling failed negative controls Technical replicates, number, calculations |

- Reaction temperatures and times
- Reaction reagents and concentrations
- Priming method
- Reaction volume, added template amount
- Inhibition assessment procedure
- □ Inhibition control description (if used)
- Number samples tested and found inhibited

- Calibration standards:
- description and source
- Method of quantifying standards Calibration curve slope
- Calibration curve R2
- Lowest standard measured or 95% LOD
- Cq value determination method

- 160
- 161
- Figure S2. EMMI checklist⁶. Details of the partition numbers and volume, and copy numbers per 162

mean, variance

Partition volume

mean, variance

example plots

analysis

Target copies per partition,

Explanation of control results,

Program used for dPCR

- 163 partition are reported in a Data Descriptor⁴.
- 164



Figure S3. The distribution of between POTW Kendalls tau values for each human viral target. There are 28 tau values for each virus (each combination of 2 POTW among the 8), and those are shown as gray circles. The box and whisker plot provides a visualization of the distribution. The whiskers extend from the 9th to 91st percentiles. The bottom and top of the box represent the 25th and 75th percentiles, the line through the middle of the box represents the median.



179

180 Figure S4. The distribution of within POTW Kendalls tau values for different human viral targets

181 comparisons (bottom axis). There are 8 tau values for each virus combination (1 for each

182 POTW), and those are shown as gray circles. The box and whisker plot provides a visualization

183 of the distribution. The whiskers extend from the 9th to 91st percentiles. The bottom and top of

the box represent the 25th and 75th percentiles, the line through the middle of the box

185 represents the median. SC2 is SARS-CoV-2. All tau values are shown, even those that are not

- 186 significantly different from 0.
- 187



188 189

190 Figure S5. Positivity rates for influenza A (IAV), RSV, human metapneumovirus (HMPV) and

SARS-CoV-2 in clinical specimens aggregated across the state of California. Data are reported
 weekly for IAV, RSV, and HMPV, and daily for SARS-CoV-2.

- 193
- 194
- 195



196

197

198

Figure S6. Panel A. Concentrations of IAV, N1, N2, H1, and H3 in copies per gram dry weight in archived samples from SJ POTW. Panel B. Distribitions of the ratio of each IAV subtype marker and IAV measured in the archived samples. Only non-zero ratios are included, aside from N1 for which all values were 0. The whiskers extend from the 9th to 91st percentiles. The bottom and top of the box represent the 25th and 75th percentiles, the line through the middle of the box represents the median.

205

206

207

208

209

211

212 Table S1. Primers and probes of previously published assays.

213

| Target | Primer/Probe | Sequence |
|-------------|--------------|--------------------------------|
| SARS-CoV-2 | Forward | CATTACGTTTGGTGGACCCT |
| N Gene | Reverse | CCTTGCCATGTTGAGTGAGA |
| | Probe | CGCGATCAAAACAACGTCGG |
| BCoV | Forward | CTGGAAGTTGGTGGAGTT |
| | Reverse | ATTATCGGCCTAACATACATC |
| | Probe | CCTTCATATCTATACACATCAAGTTGTT |
| PMMoV | Forward | GAGTGGTTTGACCTTAACGTTTGA |
| | Reverse | TTGTCGGTTGCAATGCAAGT |
| | Probe | CCTACCGAAGCAAATG |
| Influenza A | Forward | CAAGACCAATCYTGTCACCTCTGAC |
| | Reverse | GCATTYTGGACAAAVCGTCTACG |
| | Probe | TGCAGTCCTCGCTCACTGGGCACG |
| RSV | Forward | CTCCAGAATAYAGGCATGAYTCTCC |
| | Reverse | GCYCTYCTAATYACWGCTGTAAGAC |
| | Probe | TAACCAAATTAGCAGCAGGAGATAGATCAG |
| HMPV | Forward | ACTTTATTGGAGAAGGAGCAGG |
| | Reverse | GGGTAATGRTGATCAAGRTCA |
| | Probe | AYTGGATGGCMAGAACAGCA |

- 216
- 217
- 218 Table S2. Parameters used with primer design software.
- Product size ranges: 60-275
- Primer size: min 15, opt 20, max 36
- Primer melting temperature: min 50°C, optimal 60°C, max 65°C GC% content: min 40%, optimal 50%, high 60%
- concentration of divalent cations = 3.8 mM
- concentration of dNTPs needs to be 0.8 mM
- Internal Oligo: size min 15, optimal 20, max 30
- Internal Oligo: Melting temp min 62°C, optimal 63°C, max 70°C
- Internal Oligo: GC% min 30%, optimal 50%, max 80%

229

230

Table S3. Novel influenza A (IAV) H1, H3, N1, and N2 assays developed in this study. Forward and. reverse primers and probes are provided. Assays were run at 59°C annealing temperatures.

| H1 (IAV) | Forward | GTGAATCACTCTCCACAGCA | | |
|----------|---------|--------------------------|--|--|
| | Reverse | TGATTRGGCCATGAACTTGT | | |
| | Probe | TGGAACGTGTTACCCAGGAGA | | |
| H3 (IAV) | Forward | GAGRTCAGATGCACCCATTG | | |
| | Reverse | TCTGGTACATTYCGCATCCC | | |
| | Probe | TGCATCACTCCAAATGGAAGCA | | |
| N1 (IAV) | Forward | TCYCCCTTGGAATGCAGAAC | | |
| | Reverse | ACCAAGCGACTGACTCAAAT | | |
| | Probe | AGGAGYCCATATCGAACCCT | | |
| N2 (IAV) | Forward | GTGTTATCAATTTGCCCTTGG | | |
| | Reverse | GGTCCGATAAGGGGTCCTAT | | |
| | Probe | CAGGGAACAACACTAAACAACGTG | | |